WO2014100717A3 - Compositions, methods and kits for diagnosis of lung cancer - Google Patents

Compositions, methods and kits for diagnosis of lung cancer Download PDF

Info

Publication number
WO2014100717A3
WO2014100717A3 PCT/US2013/077225 US2013077225W WO2014100717A3 WO 2014100717 A3 WO2014100717 A3 WO 2014100717A3 US 2013077225 W US2013077225 W US 2013077225W WO 2014100717 A3 WO2014100717 A3 WO 2014100717A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
lung
lung cancer
subjects
Prior art date
Application number
PCT/US2013/077225
Other languages
French (fr)
Other versions
WO2014100717A2 (en
Inventor
Paul Edward Kearney
Kenneth Charles Fang
Xiao-jun LI
Clive Hayward
Original Assignee
Integrated Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/071387 external-priority patent/WO2013096845A2/en
Priority claimed from US13/775,494 external-priority patent/US9304137B2/en
Application filed by Integrated Diagnostics, Inc. filed Critical Integrated Diagnostics, Inc.
Publication of WO2014100717A2 publication Critical patent/WO2014100717A2/en
Publication of WO2014100717A3 publication Critical patent/WO2014100717A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Biophysics (AREA)
  • Bioethics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).
PCT/US2013/077225 2012-12-21 2013-12-20 Compositions, methods and kits for diagnosis of lung cancer WO2014100717A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/US2012/071387 WO2013096845A2 (en) 2011-12-21 2012-12-21 Compositions, methods and kits for diagnosis of lung cancer
US13/724,823 US9201044B2 (en) 2011-12-21 2012-12-21 Compositions, methods and kits for diagnosis of lung cancer
USPCT/US2012/071387 2012-12-21
US13/724,823 2012-12-21
US13/775,494 US9304137B2 (en) 2011-12-21 2013-02-25 Compositions, methods and kits for diagnosis of lung cancer
US13/775,494 2013-02-25

Publications (2)

Publication Number Publication Date
WO2014100717A2 WO2014100717A2 (en) 2014-06-26
WO2014100717A3 true WO2014100717A3 (en) 2014-10-30

Family

ID=50979411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/077225 WO2014100717A2 (en) 2012-12-21 2013-12-20 Compositions, methods and kits for diagnosis of lung cancer

Country Status (1)

Country Link
WO (1) WO2014100717A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11913957B2 (en) 2011-12-21 2024-02-27 Biodesix, Inc. Compositions, methods and kits for diagnosis of lung cancer
CN110114680A (en) * 2016-05-05 2019-08-09 佰欧迪塞克斯公司 For the composition of diagnosing, method and kit
KR101952649B1 (en) 2016-05-17 2019-02-27 울산대학교 산학협력단 Biomarker composition for diagnosing radiation resistant cancer or predicting prognosis of radiation therapy comprising LRP-1
US20200057068A1 (en) * 2016-11-24 2020-02-20 The Council Of The Queensland Institute Of Medical Research Determining a Cancer Prognosis
US20180299445A1 (en) * 2017-04-03 2018-10-18 Biodetego Llc Biomarkers and methods of using same
WO2019079635A1 (en) * 2017-10-18 2019-04-25 Biodesix, Inc. Compositions, methods and kits for diagnosis of lung cancer
CN113379739B (en) * 2021-07-23 2022-03-25 平安科技（深圳）有限公司 Ultrasonic image identification method, device, equipment and storage medium

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093108A1 (en) * 2006-07-08 2010-04-15 Khattar Nada H Lung cancer diagnotic assay
WO2011085163A2 (en) * 2010-01-08 2011-07-14 The Regents Of The University Of California Protein markers for lung cancer detection and methods of using thereof
WO2012075042A1 (en) * 2010-11-29 2012-06-07 Integrated Diagnostics, Inc. Diagnostic lung cancer panel and methods for its use
WO2013096845A2 (en) * 2011-12-21 2013-06-27 Integrated Diagnostics, Inc. Compositions, methods and kits for diagnosis of lung cancer
US20130230877A1 (en) * 2011-12-21 2013-09-05 Integrated Diagnostics, Inc. Compositions, Methods and Kits for Diagnosis of Lung Cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003102018A2 (en) 2002-06-03 2003-12-11 The Institute For Systems Biology Methods for quantitative proteome analysis of glycoproteins
US20070269895A1 (en) 2002-06-03 2007-11-22 The Institute For Systems Biology Methods for quantitative proteome analysis of glycoproteins
DE102004001853B3 (en) 2004-01-13 2005-07-21 Infineon Technologies Ag Fabrication of connection contacts of semiconductors for future nanotechnologies including deposition of contact layer on masking layer during later back polishing stage
EP2302393A1 (en) 2004-05-21 2011-03-30 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093108A1 (en) * 2006-07-08 2010-04-15 Khattar Nada H Lung cancer diagnotic assay
WO2011085163A2 (en) * 2010-01-08 2011-07-14 The Regents Of The University Of California Protein markers for lung cancer detection and methods of using thereof
WO2012075042A1 (en) * 2010-11-29 2012-06-07 Integrated Diagnostics, Inc. Diagnostic lung cancer panel and methods for its use
WO2013096845A2 (en) * 2011-12-21 2013-06-27 Integrated Diagnostics, Inc. Compositions, methods and kits for diagnosis of lung cancer
US20130230877A1 (en) * 2011-12-21 2013-09-05 Integrated Diagnostics, Inc. Compositions, Methods and Kits for Diagnosis of Lung Cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C LOMBARDI ET AL: "CLINICAL SIGNIFICANCE OF A MULTIPLE BIOMARKER ASSAY IN PATIENTS WITH LUNG CANCER A STUDY WITH LOGISTIC REGRESSION ANALYSIS", CHEST, vol. 97, no. 3, 1990, pages 639 - 644, XP055058289 *
JUNG-HYUN RHO ET AL: "Glycoproteomic Analysis of Human Lung Adenocarcinomas Using Glycoarrays and Tandem Mass Spectrometry: Differential Expression and Glycosylation Patterns of Vimentin and Fetuin A Isoforms", JOURNAL OF PROTEIN CHEMISTRY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 28, no. 3-4, 2 May 2009 (2009-05-02), pages 148 - 160, XP019731573, ISSN: 1573-4943, DOI: 10.1007/S10930-009-9177-0 *

Also Published As

Publication number Publication date
WO2014100717A2 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
WO2013096845A3 (en) Methods for diagnosis of lung cancer
WO2017192965A3 (en) Compositions, methods and kits for diagnosis of lung cancer
WO2014100717A3 (en) Compositions, methods and kits for diagnosis of lung cancer
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
WO2013163568A3 (en) Methods for evaluating lung cancer status
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX2017008421A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder.
MX2013002084A (en) Biomarkers and methods of treatment.
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2015031694A3 (en) Oligonucleotide probes and uses thereof
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
MX361058B (en) Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject.
ZA200908016B (en) Labelled hgf binding peptides for imaging
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2014028862A9 (en) Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
EP2971132A4 (en) Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer
WO2011015602A3 (en) Lung cancer biomarkers
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2013040251A8 (en) Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
WO2012178188A3 (en) Molecular diagnostic panel of eosinophilic gastrointestinal disorders
NZ708027A (en) Fam19a4 and hsa-mir124-2, molecular diagnostic markers for hpv-induced invasive cancers and their high-grade precursor lesions
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13824245

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13824245

Country of ref document: EP

Kind code of ref document: A2